BRIEF-Neurocrine Biosciences prices $450 mln convertible senior notes offering
* Priced offering of $450.0 million aggregate principal amount of 2.25% convertible senior notes due 2024 Source text for Eikon: Further company coverage:
Oct 10 Scandidos AB :
* Opens sales office in Asia Source text for Eikon:
Further company coverage: (Gdynia Newsroom)
LONDON, April 27 Pharmaceutical companies called on Thursday for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.